RecruitingNot ApplicableNCT07462910

Diaphragmatic Evaluation by Fluoroscopy to Identify Phrenic Nerve Dysfunction Related to Electroporation

Diaphragmatic Evaluation by Fluoroscopy to Identify Phrenic Nerve Dysfunction Related to Electroporation Prospective Multicentre Study on the Evaluation of the Incidence of Diaphragmatic Paralysis After Pulsed Field Ablation Procedures to Treat Atrial Fibrillation


Sponsor

French Cardiology Society

Enrollment

250 participants

Start Date

Jun 2, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

Pulsed Field Ablation (PFA) represents a recent advance in the treatment of atrial fibrillation (AF), with a safety profile potentially superior to traditional thermal techniques, such as radiofrequency or cryoablation. Its mechanism of action allows tissue selectivity which in theory limits damage to extracardiac structures. However, several cases of right diaphragmatic paralysis have been reported in the literature after PFA, particularly during applications on the right pulmonary veins, near the right phrenic nerve. The available data are from studies without specific diaphragmatic monitoring. The diagnosis of diaphragmatic paralysis is most often based on chest X-ray, a static examination of limited sensitivity, especially for the detection of incomplete paralysis. To date, no prospective multicentre study has evaluated the incidence of diaphragmatic paralysis after PFA with systematic dynamic imaging, such as fluoroscopy, considered the gold standard for the diagnosis of unilateral paralysis.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Men and women aged 18 years or older at the time of signing the consent (age≥ 18).
  • Diagnosis of paroxysmal or persistent atrial fibrillation, documented in any type of means: ECG, Holter, invasive monitoring (memories of an implantable device) or not (connected objects).
  • Indication for ablation decided as part of routine care, according to the recommendations of learned societies.
  • First, ablation procedure (including pulmonary vein isolation) planned with the use of a commercially available Pulsed Field Ablation catheter.
  • Possibility of performing a fluoroscopic diaphragmatic evaluation before and after the operation (before discharge from the hospital).
  • Free, informed and signed consent by the patient before any data collection

Exclusion Criteria14

  • Known history of diaphragmatic paralysis (right or bilateral) or pre-existing clinical suspicion.
  • History of atrial fibrillation ablation.
  • History of neuromuscular disease.
  • History of major thoracic surgery or chronic pulmonary pathology that may impair diaphragmatic kinetics.
  • Evidence of diaphragmatic paralysis on the pre-procedure fluoroscopy loop, defined as:
  • Cranio-caudal excursion amplitude ≤35 mm on both hemidiaphragms, Or
  • An asymmetry in contraction amplitude ≥15% between the two sides.
  • Inability to perform a post-procedure follow-up fluoroscopy (logistical limitation, patient refusal, contraindication to irradiation).
  • Pregnancy or breastfeeding in progress.
  • Concurrent participation in another interventional study that may interfere with the objectives of this research.
  • Major impairment in cognitive function or inability to understand the objectives of the study or sign a valid consent.
  • Individuals deprived of liberty by judicial or administrative decision.
  • Adults subject to a legal protection measure (guardianship, curatorship, or judicial protection/safeguard of justice).
  • Individuals unable to provide informed consent.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREDynamic fluoroscopy

Fluoroscopic loop recording or continuous digital scopy of the thoracic window, over at least one complete breathing cycle at maximum amplitude.


Locations(9)

Montreal Heart Institute

Montreal, Canada

CHRU de Tours - Hôpital Trousseau

Chambray-lès-Tours, France

CHU de Lyon - Hôpital Croix-Rousse

Lyon, France

Centre Hospitalier de Pau - Hôpital François Mitterrand

Pau, France

CHU de Bordeaux - Hôpital Haut-Lévêque

Pessac, France

Centre Cardiologique du Nord

Saint-Denis, France

Institut Cardiovasculaire de Strasbourg - Clinique Rhéna

Strasbourg, France

Clinique Pasteur

Toulouse, France

Auckland City Hospital

Auckland, New Zealand

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07462910


Related Trials